Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019

February 1, 2019 – EMA’s human medicines committee (CHMP) recommended six medicines for approval at its January 2019 meeting. The CHMP adopted a positive opinion for Fremanezumab, for the prophylaxis of migraine. Dacomitinib received a positive opinion for the treatment of locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor activating mutations. Two biosimilar medicines for the treatment of certain … (leggi tutto)